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International lessons in new methods 
for grading and integrating cost effectiveness 
evidence into clinical practice guidelines
Kathryn M. Antioch1, Michael F. Drummond2, Louis W. Niessen3* and Hindrik Vondeling4
Abstract 
Economic evidence is influential in health technology assessment world-wide. Clinical Practice Guidelines (CPG) can 
enable economists to include economic information on health care provision. Application of economic evidence in 
CPGs, and its integration into clinical practice and national decision making is hampered by objections from profes-
sions, paucity of economic evidence or lack of policy commitment. The use of state-of-art economic methodologies 
will improve this. Economic evidence can be graded by ‘checklists’ to establish the best evidence for decision making 
given methodological rigor. New economic evaluation checklists, Multi-Criteria Decision Analyses (MCDA) and other 
decision criteria enable health economists to impact on decision making world-wide. We analyse the methodolo-
gies for integrating economic evidence into CPG agencies globally, including the Agency of Health Research and 
Quality (AHRQ) in the USA, National Health and Medical Research Council (NHMRC) and Australian political reforms. 
The Guidelines and Economists Network International (GENI) Board members from Australia, UK, Canada and Den-
mark presented the findings at the conference of the International Health Economists Association (IHEA) and we 
report conclusions and developments since. The Consolidated Guidelines for the Reporting of Economic Evaluations 
(CHEERS) 24 item check list can be used by AHRQ, NHMRC, other CPG and health organisations, in conjunction with 
the Drummond ten-point check list and a questionnaire that scores that checklist for grading studies, when assessing 
economic evidence. Cost-effectiveness Analysis (CEA) thresholds, opportunity cost and willingness-to-pay (WTP) are 
crucial issues for decision rules in CEA generally, including end-of-life therapies. Limitations of inter-rater reliability in 
checklists can be addressed by including more than one assessor to reach a consensus, especially when impacting on 
treatment decisions. We identify priority areas to generate economic evidence for CPGs by NHMRC, AHRQ, and other 
agencies. The evidence may cover demand for care issues such as involved time, logistics, innovation price, price 
sensitivity, substitutes and complements, WTP, absenteeism and presentism. Supply issues may include economies 
of scale, efficiency changes, and return on investment. Involved equity and efficiency measures may include cost-of-
illness, disease burden, quality-of-life, budget impact, cost-effective ratios, net benefits and disparities in access and 
outcomes. Priority setting remains essential and trade-off decisions between policy criteria can be based on MCDA, 
both in evidence based clinical medicine and in health planning.
JEL Classification:  I1: health, D61: cost benefit analysis, I180: Health-Government policy, Regulation, Public health, 
O320: management of technological innovation and R&D
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cost Effectiveness and 
Resource Allocation
*Correspondence:  Louis.Niessen@lstmed.ac.uk; l.niessen@warwick.ac.uk 
3 GENI Board, Warwick Medical School, Liverpool School of Tropical 
Medicine, Pembroke Place, Liverpool L3 5QA, UK
Full list of author information is available at the end of the article
Page 2 of 15Antioch et al. Cost Eff Resour Alloc  (2017) 15:1 
Background
Economic evidence is becoming influential in health 
technology assessment (HTA) world-wide. However, 
most health care practices and procedures are not sub-
jected to HTAs, thereby limiting the impact of economic 
evidence. CPGs offer the potential for economists to be 
centrally involved in increasing the cost-effectiveness of 
health care provision. However, examples of the use of 
economic evidence in such guidelines, and the subse-
quent integration of such evidence into clinical practice 
and national decision making are limited. This may be 
because of resistance from the professions, paucity of 
economic evidence or lack of policy commitment.
Important components of the evidence used in the 
development of CPGs include the use of systematic 
reviews of the literature, decision rules, WTP, opportu-
nity costs, and end of life/social value judgement along 
with techniques to grade the economic evidence. Such 
evidence can be graded by guidelines or ‘checklists’ to 
establish which evidence should be used to inform deci-
sions based on the rigor of the methodology. New devel-
opments in all of these areas are cutting edge techniques 
that provide a platform for improved contribution by 
health economists in decision making world-wide and 
are considered in this paper. The principal purpose of this 
paper is to address the implications of these methodolo-
gies for the integration of economic evidence into CPG 
agencies world-wide and their implications for Australian 
reforms by the Parliament, governments and health ser-
vices. These issues were discussed by Board members of 
the Guidelines and Economists Network International1 
(GENI) in presentations at the 9th IHEA World 
Congress.
The GENI is an international association which enables 
health economists, epidemiologists, clinicians and medi-
cal experts world-wide to work with prominent interna-
tional bodies, health services and governments. GENI’s 
agenda is to facilitate the effective integration of CPGs, 
economic and clinical evidence into national decision 
making and clinical practice in the health sector. GENI 
aims to forge linkages with bodies that set the standards 
for appropriate treatment under different conditions that 
may link to contracts or regulatory processes such as 
insurers and national government funding systems. Link-
ages to Evidence Based Medicine (EBM), service delivery 
and related government regulatory and funding systems 
are central. GENI’s has twelve international board mem-
bers and a large twenty-nine member management team 
comprising CEO, Medical Advisory Committee, Direc-
tors, senior managers and researchers, with over 830 
GENI LinkedIn Group affiliates.
1 http://geni-econ.org/.
At the 9th IHEA Congress, five of GENI’s Board mem-
bers from America, UK, Australia, Canada and Denmark 
discussed new methodologies and economic guidelines 
or ‘checklists’ for incorporating economic evidence into 
CPGs, clinical practice and national decision making. 
The session considered guidelines recently developed 
for the conduct and reporting of economic evaluations. 
These guidelines assess studies for decision-making in 
technology assessment for reimbursement or developing 
CPGs. The session also discussed use of CEA evidence 
in CPG processes in Australia by NHMRC, three Local 
Hospital Networks (LHNs) in Victoria and implications 
for related national and state health policy reforms led 
by the Council of Australian Governments (COAG) and 
reviewed by the Australian Parliament. An impetus for 
the international discussion at IHEA was a request from 
the NHMRC for input from GENI about the Council’s 
review of its processes to develop and approve guidelines 
in Australia using the costs and benefits evidence and 
also socio-economic evidence. The focus on these evi-
dence based medicine (EBM) approaches involving CPGs 
and CEA evidence has also been an important feature 
in some reforms by the Australian Parliament, Govern-
ments and health services. The methodologies discussed 
in this paper may further assist this reform agenda, along 
with the deliberations of the NHMRC and other regula-
tory bodies that approve CPGs world-wide.
Firstly, we discuss Australian health policy reforms in 
Commonwealth-State health agreements involving, inter 
alia, national implementation of LHN governance struc-
tures and hospital Activity Based Funding (ABF) based 
on the Victorian model. Recommendations were pro-
vided to COAG and the Senate based on Victorian evalu-
ations of applications of NHMRC’s CPG methods using 
CEA in Victorian LHNs and the risk adjustment of ABF, 
given relevance to legislation for health agreements and 
related authorities. The Senate also considered reforms 
for palliative care, rural health and the Aged Care Qual-
ity Agency and recommendations were submitted to the 
Senate about crucial CPG and CEA issues. COAG’s 2016 
Heads of Agreements on Public Hospital Funding will 
reduce ABF for specified adverse events, ineffective or 
harmful treatments and readmissions. Recommendations 
to the Senate about risk adjusting ABF and measure-
ments of quality outcomes and disseminating NHMRC’s 
EBM methods Australia-wide are also discussed. The 
NHMRC’s CPG development process review is then 
considered.
That is followed by consideration of the CHEERS Task 
Force which has consolidated guidelines for assessing 
health economic evaluation studies and recently pub-
lished a consensus statement, along with the check-
list. Recent developments for MCDA that broaden the 
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objectives of evaluation in health care are considered 
along with the International Society for Pharmaco-
economics and Outcomes Research’s (ISPOR) MCDA 
Emerging Good Practices Task Force that has developed 
a common definition for MCDA in health care and good 
practice guidelines for conducting MCDA. The Hopkins 
Review is then discussed which examines if and how 
economic evidence impacts on health policy, includ-
ing clinical guidelines, in the USA. It also examines the 
strengths and weaknesses of existing checklists used to 
assess best practices in economic evaluations. The review 
of studies also addresses the use of economic outcomes 
in policy and decision making. Finally, we conclude with 
implications of these deliberations world-wide for health 
services, governments and agencies that develop CPGs 
such as National Institute of Health and Care Excellence 
(NICE), US Guidelines clearing house, NHMRC and the 
USA Centre for Disease Control and Prevention (CDC).
Review
Lessons for Australian parliament, National Health 
and Medical Research Council, Governments and Health 
services
Australian Commonwealth‑State Health agreements 
and reforms
In Australia, there are several agreements between Com-
monwealth and State governments through the Coun-
cil of Australian Governments (COAG), that specify 
health policy and reform directions, including the 
National Healthcare Agreement (NHA), the National 
Health Reform Agreement (NHRA), National Partner-
ship Agreements and the Intergovernmental Agreement 
on Federal Financial Relations. Further, the April 2016 
Heads of Agreement on Public Hospital Funding forms 
the basis of negotiations leading towards a time-limited 
addendum of the NHRA, in the form of an additional 
schedule, to commence on 1 July 2017.
This suite of Agreements is designed to set out the 
architecture for a nationally unified and locally controlled 
health system. They also encourage improved quality of 
care and the cost-effective use of guidelines, clinical path-
ways and other EBM initiatives [1].
Antioch briefed COAG during 2008, 2009 and 2010 
about the new health agreements. She also briefed the 
Australian Senate from 2010 to 2013 on COAG Agree-
ments and related authorities and, in 2016, on new 
COAG Heads of Agreements. Some briefs included evi-
dence that implementing NHMRC methodologies for 
CPG implementation with economic and clinical evi-
dence in Victorian LHNs resulted in cost effective service 
provision in the context of ABF. She recommended the 
development of State Centres of EBM Health Services and 
Workforce Redesign, use of NHMRC and international 
methods with economic and clinical evidence. an Inter-
national Centre of EBM and Health Economics and the 
need for adequate risk adjustment of ABF [2–4].
Antioch’s [2] COAG brief addressed a reform agenda 
for the 2009 Australian Healthcare Agreements (AHA) 
re-negotiation involving two areas. Firstly, she proposed 
new state centres to integrate the economic and clinical 
evidence and CPGs into clinical practice using methods 
by the NHMRC [5–9], Antioch et  al. [10], Drummond 
et al. [11] and organisations such as GENI. Secondly, she 
argued the equity of the AHCA formulae and index can 
be improved using risk adjustment to align funding with 
health need by using either Diagnostic Cost Group-Hier-
archical Condition Categories (DCG-HCC) relative risk 
scores or Diagnostic Related Group (DRG) cost weights, 
Evidence she published in European Journal of Health 
Economics concerning risk adjustment requirements for 
the ABF formulae in Victoria relating to severity markers 
for state-wide referral services e.g. transplantation, major 
trauma was also referenced [2, 12].
Antioch’s [3] COAG brief outlined national cost savings 
of $273.524  m pa (2006 prices) and $1367.620  m over 
five years via implementation of the proposed State Cen-
tres, modelled on cost savings achieved by reductions of 
adverse events and length of stay in the Victorian hospital 
experience. That brief attached advice from the North-
ern Territory (NT) Health Minister who expressed inter-
est in risk adjustment for ABF implementation given the 
demographic and geography of NT are such that the use 
of a standard Australian profile runs a severe risk of the 
jurisdiction being disadvantaged [3]. The ABF formulae 
subsequently developed by the Australian Government 
included a risk adjustment to the formulae called ‘indig-
enous adjustment’ which still remains along with other 
adjustments [13].
Antioch’s COAG brief, which was also published by 
the Senate Standing Committee on Finance and Public 
Administration Inquiry into COAG Reforms relating to 
Health and Hospitals [4], stated that some Health Min-
isters advised that their Departments were consider-
ing her reform proposals for their implementation of 
the National Health Agreements and Partnership pro-
grams, with one large jurisdiction indicating that the 
State planned to introduce a State Centre similar to her 
proposed State Centres. The brief also recommended 
the establishment of an International Centre of Evidence 
Based Medicine and Health Economics.
Antioch’s COAG and Senate submissions indicated that 
the ‘State Centres’ recommendation arose from national 
stakeholder engagement during her 2007 presentations 
in all Australian States and Territories and NZ about the 
implementation and evaluation of the initiatives she led 
in the Victorian LHNs and subsequent liaison with the 
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Federal Health Ministers’ Office. The national presenta-
tions were sponsored by the Australian Health Care and 
Hospital Association and the Women’s and Children’s 
Hospital Australasia in the context of the renegotiation 
of National Health Agreements. She provided a Cost 
Benefit Analysis (CBA) of national implementation of 
the State Centres in her invited submission to the Sen-
ate Inquiry concerning the establishment of the National 
Health Performance Authority and also the Independent 
Hospital Pricing Authority which calculated net benefits 
of $269.6 m per annum (2006 prices) [14, 15]. The CBA 
was modelled on the evaluation of the Victorian LHN ini-
tiatives. Many features of the national reforms by COAG, 
and under consideration by then Australian Parliament, 
were based on the Victorian health system including ABF 
and new hospital network governance through LHNs. 
Evidence of cost effective EBM implementation in Victo-
ria was of interest.
Australian parliament inquiries on health agreement 
legislation and health policy reforms
Parliamentary Inquiries since 2010 made recommenda-
tions about policy and legislation to implement elements 
of the Health Agreements and other health policy. The 
Senate Report on the Federal Finance (National Health 
and Hospitals Network) Bill [16] cited Victorian health 
system effectiveness and efficiency evidence provided by 
Antioch [17] in support of the new national arrange-
ments. The Committee recommended that the Senate 
pass the Bill and recognized the Bill is ‘a vital piece of leg-
islation which will enable the implementation of signifi-
cant elements of the health and hospital reforms agreed 
by COAG in April 2010′. Economics Legislation Senate 
Committee [16]. More recently, various State govern-
ments are implementing State Centres to facilitate best 
practice and innovation in NSW, Victoria and Queens-
land.2 The methodologies in this paper and deliberations 
of more recent Senate Inquires in 2012, 2013 and 2016 
outlined below could assist such State Centres along with 
Australian governments, health services and the 
NHMRC.
The Senate Inquiries during 2012 into Palliative Care 
in Australia and Factors Affecting the Supply of Health 
Services and Medical Professionals in Rural Areas 
addressed CPGs and the use of health economics to 
improve efficiency, outcomes and prioritization of health 
2 This includes the Agency for Clinical Innovation (ACI) and Centre for 
Health Care Redesign in NSW and the Centre for Health Care Improve-
ment in Queensland. In Victoria the Commission for Hospital Improvement 
and the Health Innovation and Reform Council were created. More recently 
the Victorian Commission was disbanded and replaced by Better Care Vic-
toria.
technologies and service delivery. Stakeholders in the 
Palliative Care Inquiry advocated urgent updated CPGs 
for palliative care, advanced care directives, dementia 
diagnosis, pain management and case management to 
enable improvements in cost effective service provi-
sion and continuum of care. Antioch recommended that 
CPG updates by COAG, Federal Department of Health 
and NHMRC could use CPGs by NICE and Agency for 
Healthcare Research Quality (AHRQ) USA CPG Clear-
inghouse concerning opioids, advanced care directives/
planning and radiotherapy. She advocated that CEA evi-
dence for new Australian CPGs in palliative care should 
be based on NHMRC methodologies [18]. The Senate 
report on Palliative Care in Australia recommended that 
COAG should consider developing and implementing 
a case management model; and a uniform national pal-
liative care pathway that clarifies when general palliative 
care moves into specialist palliative care, and maps the 
diagnosis and referral process to ensure that a palliative 
patient’s journey involves coordinated access to all neces-
sary services. It also recommended that a national model 
legislation for advanced care planning should be devel-
oped and the NHMRC should report its work on alterna-
tive therapy claims in relation to palliative care [19].
Stakeholders in the 2012 Rural Health Senate Inquiry 
argued for urgent mechanisms for rapid EBM transla-
tion of CEA evidence and CPGs into rural practice with 
the input of economists. They also advocated improved 
Evidence Based Planning (EBP) to identify rural sup-
ply and demand factors and prioritisation. Antioch [20] 
recommended that the Federal government undertake 
a national review of EBM translational work to prevent 
duplication, with a consolidated and rapid disseminate 
EBM evidence to rural areas. For EBP she recommended 
the uptake of evidence concerning disease burden, epi-
demiological data and CEA of interventions, for demand 
and supply modelling. Any gaps in the evidence identi-
fied in the national review should be addressed by Fed-
eral and State governments, NHMRC and all States 
[20]. A key Senate Committee recommendation was for 
the Department of Health and Ageing to prepare a brief 
for COAG’s Standing Council on Health on existing or 
emerging gaps affecting the delivery of health services to 
rural and remote communities caused by mis-alignment 
between Commonwealth and state policy, including 
options for measures to remediate such gaps [21].
Antioch [22] recommended to the 2013 Senate Inquiry 
on the Aged Care Quality Agency Bill 2013 that the 
Agency, which is the new accreditation body, should 
include health economists and indigenous health experts 
and should collaborate with the NHMRC, GENI, Aus-
tralian Commission on Safety and Quality in Health 
Care (ACSQHC), Cochrane Collaboration, Guidelines 
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International Network (GIN), National Guideline Clear-
ing House AHRQ, NICE, NHS Economic Evaluation 
Database (NHS EED), NHS Evidence, WHO Health Eco-
nomics Network and the CDC. That Committee consid-
ered five Bills on Aged Care of which the Quality Agency 
was one. The Senate Committee’s Report recommended 
monitoring the impacts of fee scales on client welfare and 
providers, and new supplements for the homeless and 
workforce. The report addressed guidelines from the per-
spective of home care packages based on clinical need, 
accreditation of residential care services, workforce sup-
plements and pricing [23].
Under the April 2016 COAG heads of agreement, 
which cover public hospital funding from 2017 to 2020, 
the Commonwealth will provide $2.9  b in additional 
funding but growth is capped at 6.5% with some fund-
ing linked to quality outcomes. The agreements will 
reduce payments for specified adverse events, ineffec-
tive interventions, procedures known to be harmful and 
readmission rates and the Independent Hospitals Pric-
ing Authority (IHPA) is working with the ACSQHC and 
COAG to develop implementation details [24], Antioch 
[24] recommended the risk adjustment of all compara-
tive hospital data to capture, inter alia, the impact of 
state-wide referral services on case-mix severity and 
emphasised that reductions in funding can unfortunately 
further exacerbate adverse quality outcomes for some 
conditions such as certain infections. The Committee 
concluded that ‘the gap in health and education funding 
remains. The Government remains committed to policies 
that deprive these areas of the much needed funds’ [25].
In response to the Senate Select Committee on Health 
Inquiry on Health Policy, Administration and Expendi-
ture in 2016, Antioch [26] recommended that, in con-
junction with the COAG 2016 Health Agreements and 
associated ABF linking risk adjusted quality outcomes 
to funding, COAG should facilitate dissemination of 
NHMRC’s methods for using the costs and benefits evi-
dence in CPGs Australia-wide and the revised methods 
once finalised [26]. The Inquiry recommended that the 
Government should determine that the implementa-
tion mechanisms for ABF should not be dismantled 
and a body similar to the National Health and Hospitals 
Reform Commission should be reconstituted [27]. We 
now turn to the NHMRC review of CPG development 
processes in Australia.
NHMRC review of Australian clinical practice guideline 
development and approval methodologies
NHMRC is reviewing its CPG development and imple-
mentation methods, including the use of economic evi-
dence and requested advice from GENI on use of the 
costs and benefits and socio-economic evidence. The 
advice was provided to the NHMRC in September 2013 
and was based on the issues cited herein to 2013. More 
recent issues covered can further facilitate NHMRC’s 
review which is still underway. The NHMRC [28] ‘Proce-
dures and Requirements for Meeting the 2011 NHMRC 
Standard for Clinical Practice Guidelines document pro-
vides direction for CPG developers who must initially 
register their guidelines in the NHMRC Development 
Register and include evidence about needs analysis, dis-
ease burden and the clinical problem to be addressed. 
NHMRC then notifies the Australian Health Ministers 
Advisory Council if CPGs have been accepted for con-
sideration. The CPG drafts are assessed using the AGREE 
II tool. The CPG drafts are forwarded to the Therapeu-
tics Goods Administration (TGA), Pharmaceutical Ben-
efits Advisory Committee (PBAC), Medical Services 
Advisory Committee (MSAC) and Health Departments 
for comment. The NHMRC’s current review of its CPG 
processes and standards aims to improve development 
and implementation of CPGs, public health guidelines, 
systematic reviews and decision making. This review 
involves NHMRC Principal Committees, NHMRC Syn-
thesis and Translation of Research Evidence Advisory 
Group 2014-16 with Working Groups formed from 
NHMRC’s Research Translation Group (RTG) Advisors 
List. The current NHMRC standards [28] handbooks 
on CPGs [5–9, 29, 30] and methodological guidance by 
AHRQ and NICE will be considered. The NHMRC [28] 
Standards refer to the publication ‘NHMRC additional 
levels of evidence and grades of recommendations for 
developers of guidelines’ (NHMRC 2009) [30]. However, 
NHMRC [30] does not address the economic evidence. 
Rather, economic evidence is only addressed in ‘How to 
compare the costs and benefits: evaluation of the eco-
nomic evidence [9]. The NHMRC’s [28] standards state 
that the NHMRC desires input on CEA of interventions 
to be included in guidelines. Hence, economic issues are 
important. NHMRC Standard C. 3.4 states the evidence 
review should involve search strategies for cost effec-
tiveness, and resource implications of practice. NHMRC 
Standard D.9.2 indicates that guideline recommendations 
should consider resource implications and cost effec-
tiveness of recommended practice compared to current 
practice. NHMRC Standard G.4 indicates that resources 
for guideline implementation should be considered. 
The NHMRC [9] handbook on how to evaluate the eco-
nomic evidence uses Drummond et al. “10 point” check 
list [11] and assesses whether there is a well-defined 
question, a comprehensive description of alternatives is 
provided, effectiveness is established. All relevant cost 
and consequences are included along with appropriate 
measurement. It also assesses credible valuation, differ-
ential timing, incremental costs and consequences, and 
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whether allowance is made for uncertainty and appropri-
ate interpretation of results [9]. The matrix in Table 1 is 
used to make decisions about the new technology given 
the strength of evidence for outcomes and costs [9]. The 
methods for the economic evaluation of health care pro-
grammes and treatments have also been discussed in 
the requirements of other decision-making bodies, such 
as the National Institute of Health and Care Excellence 
(NICE) in the UK, which uses the NICE Reference Case, 
considered in more detail later. The reporting of eco-
nomic evaluations of health interventions is challeng-
ing because substantial information must be provided to 
enable the scrutiny of findings. Despite a growth in pub-
lished reports in recent years, reporting guidelines have 
not being widely adopted. There has been a need to con-
solidate and update existing guidelines in a user-friendly 
manner. Checklists can assist peer reviews, authors, and 
editors, to use consistent guidelines to improve reporting. 
The Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS statement consolidates and updates 
previous health economic evaluation guidelines into one 
current, useful reporting guidance.
The ISPOR 2013 CHEERS 24 item check list, dis-
cussed more fully in the next section, can be used by 
the NHMRC, in conjunction with Drummond et  al’s 10 
point check list, when assessing the economic evidence. 
A questionnaire by Antioch, Jennings, Botti et  al. [10] 
published in the European Journal of Health Econom-
ics, that scores Drummond et al. [11] 10 point check list, 
has been used in Australia since 2000 to grade the cost 
effectiveness evidence using NHMRC methods and CEA 
thresholds for making recommendations about changes 
to clinical guidelines and for implementing evidence in 
three Victorian Local Hospital Networks. Since 2013, 
that questionnaire [10] has been used in Australia in con-
junction with CHEERS assessments which enables an 
in-depth analysis of issues covered in the Drummond’s 
10-point checklist. This work on grading the CEA evi-
dence in systematic reviews to evaluate CPGs for dis-
eases such as diabetes type 2 and cystic fibrosis involves 
senior members of public and private hospitals, national 
associations, universities, and GENI’s senior manage-
ment team.
We outline below international findings that can also 
guide NHMRC’s review of CEA thresholds for CPG 
development and approval. CEA studies should identify 
the health benefits offered by an intervention; the addi-
tional costs imposed on a limited healthcare budget; and 
the opportunity costs (i.e. health benefits forgone) from 
commitment of resources to an intervention. An inter-
vention can be considered cost-effective if its benefits 
outweigh the opportunity costs of health benefits for-
gone. The opportunity costs in terms of forgone health 
benefits are reflected in most CEAs by using a cost-effec-
tiveness threshold (CET) [33].
When the maximum acceptable trade-off between 
costs and effectiveness is known, CEA can inform 
whether a program providing a trade-off between its 
costs and its effectiveness should be implemented. By 
using the maximum WTP per Quality-Adjusted Life Year 
(QALY), one can establish a decision rule for CEA. This 
view emanates from welfare economics, which states that 
welfare is maximized if goods are exchanged when there 
is a maximum WTP that exceeds the opportunity cost of 
the good [31]. The NHMRC defines its CEA threshold or 
‘shadow prices’ as is the predetermined maximum WTP 
for health gains [9].
CEA used by NICE is an assessment of whether the 
health expected to be gained from using a new medi-
cal technology exceeds the health likely to be forgone as 
other NHS activities are displaced to accommodate the 
additional costs of the new technology. The CEA thresh-
old therefore represents an estimate of the health forgone 
as services are displaced [32].
The challenge for decision makers is to determine and 
use CETs that reflect supply-side constraints. However, 
there are few empirically estimated supply-side CETs. 
One exception is Claxton et al. [33] study that estimated 
the marginal productivity of the UK National NHS and 
produced a best estimate of the supply-side CET of 
£12,936, about half of UK GDP pc. [33].
Claxton et  al. [33] estimated the effects of changes in 
NHS expenditure on the health of all NHS patients and 
found that NICE’s CEA threshold used to assess new 
drugs is too high. The approval of new drugs is therefore 
causing more harm than good to NHS patents overall 
given the NHS is paying too much for new drugs. NICE 
has applied £30,000 per QALY threshold to determine 
whether health benefits of a new drug are greater than the 
health likely to be lost because the additional resources 
required are not available to offer effective treatments 
Table 1 Assessing CEA evidence using shadow prices 
in Australia: NHMRC [9]
Ranking of evidence 
on costs
Ranking of evidence on effects
High Low
Strong Recommend if: Recommend if:
<$70,000 per life-year <$30,000 per life-year
Do not recommend if Do not recommend if
>$100,000 per life-year >$70,000 per life-year
Weak Recommend if: Recommend if:
<$30,000 per life-year <$30,000 per life-year
Do not recommend if Do not recommend if
>$70,000 per life-year >$30,000 per life-year
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to other NHS patients. Claxton et  al. [33] found that 
the threshold is too high as their best empirical esti-
mates, based on a number of assumptions, was £12,936 
(rounded £13,000) of NHS resources adds one QALY to 
the lives of NHS patients. Greater harm is therefore being 
done to other NHS patients when NICE approves costlier 
drugs. The approval of a new drug that costs the NHS an 
additional £10 m per annum would offer benefits of 333 
QALYs. It would also lead to the loss of 773 QALYs for 
other NHS patients with increased mortality in circula-
tory, cancer, gastro-intestinal or respiratory diseases and 
reduced quality of life in mental health and neurological 
diseases. This represents a net loss of 440 QALY for every 
£10 m of additional NHS costs. Further, devoting £280 m 
to the Cancer Drugs Fund in 2014/15 has been associated 
with a loss of 21,645 QALYs for other NHS patients [33, 
34].
NHMRC [9] includes additional criteria which allow 
higher prices for CEA thresholds for criteria such as: 
quality of life for patient and/or family; survival improve-
ment; functional status; condition is severe, rare, pre-
ventable, or leads to permanent effects in youth; no other 
health care options available and intervention prevents 
adverse flow-on effects into other sectors with equity 
implications. Health care options might require further 
consideration with regard to these social values if they 
fall in the range $70,000–$100,000 per life-year saved and 
rank highly for evidence on costs and effects, or if they 
are in the range $30,000–$70,000 per life-year saved and 
rank highly on one but not the other [9].
Other developments about CEA thresholds in Aus-
tralia are important to consider. Australia has public 
insurance coverage for drugs through the Pharmaceuti-
cal Benefits Scheme (PBS). Harris et  al. [35] found that 
the Pharmaceutical Benefits Advisory Council (PBAC) 
decided drug approval coverage from 1994 to 2004 with-
out reference to a public CEA threshold for the cost per 
LYG or QALY. WTP and decisions were based on the 
clinical significance, CEA results, cost to government and 
disease severity. Clinical significance increased the prob-
ability of recommending coverage by 0.21 and a drug for 
a ‘life threatening’ condition increased that probability 
by 0.38. Increases of $A10,000 from an incremental cost 
per QALY of $A46,400, reduced the probability of listing 
by 0.06 [35]. Harris et al. [36] analysed 1993–2009 PBAC 
funding decisions. They found that an A$10,000 increase 
in cost per QALY reduces average probability of funding 
from 37 to 33%. For life threatening conditions or where 
the drug has no active comparator, odds of positive rec-
ommendation are 3.18 and 2.14 greater. If both condi-
tions are met, the odds are increased by 4.41 times [36].
Shiroiwa, Sung and Fukuda et  al. [37] note that 
although CEA thresholds for medical interventions are 
assumed to be $50,000–$100,000 in the US and 20,000–
30,000 UK pounds in the UK such values are unjusti-
fied, given lack of evidence. They measured WTP for one 
additional QALY gained to determine the threshold of 
the incremental cost-effectiveness ratio. They compared 
WTP for the additional year of survival in a perfect status 
of health in Japan, the Republic of Korea (ROK), Taiwan, 
Australia, the UK, and USA. A double-bound dichoto-
mous choice was used, and analysis by the nonparamet-
ric Turnbull method. WTP values were JPY 5 million 
(Japan), KWN 68 million (ROK), NT$2.1 million (Tai-
wan), 23,000 UK pounds (UK), AU$64,000 (Australia), 
and US$62,000 (US). The discount rates of outcome were 
estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 
2.8% (UK), 1.9% (Australia), and 3.2% (US). They recom-
mended a new classification of cost-effectiveness plane 
and methodology for decision making [37].
Importantly, Drummond et  al. [38] note that NICE 
has developed supplementary guidance for ‘end of life’ 
therapies in the circumstance where the therapy is for a 
small patient population with life expectancy of less than 
24 months and where the therapy adds three months or 
more to life expectancy. In this scenario, QALYs gained 
should assume full quality-of-life in the added months. 
In addition, the Committee can consider that the QALYs 
gained should be weighted sufficiently high for the 
therapy to be approved, given NICE’s current thresh-
old. These findings along with Harris et al. [35, 36], Shi-
roiwa et  al. [37] could inform NHMRC’s consideration 
of revised thresholds for CEA in its review of CPG pro-
cesses and in other countries.
We now consider the CHEERS guidelines, which con-
solidate previous health economic evaluation guidelines. 
Requirements of other decision making bodies such as 
NICE, which uses the NICE Reference Case are also con-
sidered and may be instructive for deliberations of other 
CPG Agencies, including the NHMRC.
Consolidated guidelines for the reporting of economic 
evaluations: the CHEERS task force—reporting guidelines 
for economic evaluation
The ‘CHEERS Elaboration and Explanation Report of the 
ISPOR Health Economic Evaluation Publication Guide-
lines Good Reporting Practices Task Force’ facilitates the 
use of the CHEERS statement by providing examples and 
explanations for each recommendation [39].
If economic considerations are to be incorporated 
into clinical guidelines, the guidelines need to reflect 
the current knowledge on the cost-effectiveness meth-
odology. Therefore, guideline developers need to con-
sult the existing literature on economic evaluation of 
health care treatments and programmes. The methods 
for the economic evaluation of health care programmes 
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and treatments have been discussed in the academic lit-
erature [11] and in the requirements of decision-making 
bodies, such as NICE in the UK which uses the NICE 
Reference Case [40]. The NICE Reference Case requires 
submission for product review to conform to the fol-
lowing standards: a decision problem defined by NICE 
scope; comparator therapies listed in NICE scope; inclu-
sion of all direct health effects for patients and caregiv-
ers; costs incurred by NHS and Personal Social Services 
(PSS), cost-utility analysis with full incremental analysis; 
time horizon long enough to reflect all important differ-
ences in costs and outcomes between technologies being 
compared; claims for health effects based on systematic 
review; health effects expressed as QALYs with EQ-5D 
the preferred instrument; data for health related quality 
of life measurement reported by patients and/or caregiv-
ers; preference data for valuation of changes in health 
related quality of life obtained from a representative 
sample of UK population; QALYs all have equal equity 
weight; resource use and costs valued using prices rel-
evant to NHS and PSS; costs and benefits should be dis-
counted at same annual rate (3.5%) (NICE [40], Langley 
[42]).
Application of these standards for chronic disease 
interventions involves modelling the natural disease pro-
gression and the impact of competing interventions over 
the patient’s lifetime or similar long-term time horizon. 
Disease progression stages can involve a Markov process 
to track a hypothetical cohort of patients through disease 
stages. Each health state is defined via associated utilities 
and costs, with results expressed as cost per QALY [42]. 
The Markov process often involves two methods of eval-
uation. Cohort simulation tracks a hypothetical cohort of 
patients simultaneously through the model. Monte Carl 
simulation randomly selects a patient from the cohort 
and each patient transits through the model one at a time 
[43]. By application of a WTP threshold cost per QALY, 
products are judged acceptable, rejected or accepted 
after agreement on a the actual price set [42].
Although various aspects of the methods of economic 
evaluation are a continuing source of debate, there is 
much more agreement about the need for reporting 
standards for studies. That is, although different studies 
may use different methods, all researchers should have 
an obligation to report their studies in a transparent fash-
ion. This will help guideline developers and other users of 
economic evaluations to benefit the most from the exist-
ing literature. The most recent attempt to specify report-
ing guidelines for economic evaluations is the CHEERS 
initiative [39].
The CHEERS Standards were developed by the Good 
Research Practices Task Force established by the Inter-
national Society for Pharmacoeconomics and Outcomes 
Research (ISPOR). The Task Force comprised specialists 
in the economic evaluation of health care programmes 
and the editors of journals publishing cost-effectiveness 
studies of health care interventions. The reporting guide-
lines were developed through a process consistent with 
that of the CONSORT initiative for developing guidelines 
for the reporting of clinical trials [41].
The CHEERS guidelines shown in Additional file  1: 
Appendix S1 assess studies with regard to conflict of 
interest and funding sources in addition to traditional 
components of published health economic evaluations 
that involve the title, abstract, introduction, methods and 
discussion. Economic evaluation methods are assessed 
with regard to the target population and sub-groups, set-
ting and location, study perspective, comparators, time 
horizon, discount rate, choice of health outcomes, meas-
urement of effectiveness and evaluation of preference 
based outcomes, estimates of resource and costs, cur-
rency, price date, conversions, choice of model, assump-
tions and analytic methods. Results are assessed in terms 
of study parameters, incremental costs and outcomes and 
characterising uncertainty and heterogeneity. Research 
findings, limitations, generalizability and current knowl-
edge are assessed in the study’s discussion [39].
One point to note is that, on occasions, the guidelines 
differ for economic evaluations conducted alongside a 
single clinical study (e.g. a clinical trial) and those con-
ducted as part of a decision analytic model, involving the 
synthesis of data from a number of sources. Several issues 
arose during the development of the CHEERS guidelines. 
The main issue related to whether reporting guidelines 
should merely require the authors of a study to describe 
their methods, or whether authors should describe and 
explain why they had adopted a particular approach. A 
good example of this is the selection of comparators. 
The CHEERS group felt that, in addition to describing 
the comparators included in their study, authors should 
also give their rationale for the selection e.g. One ration-
ale would be to include the current standard of care in 
the jurisdiction where the study was conducted [39]. The 
CHEERS checklist enables detailed analysis of the items 
in Drummond’s 10 point checklist thereby facilitating 
comprehensive scoring of Drummond’s checklist using 
the EJHE questionnaire [10] to grade the evidence.
Structuring complex evidence and values using 
multi‑criteria decision analysis (MCDA)
During the 1970s and 1980s there was debate in the eco-
nomics and ethics literature about relevant criteria for 
making resource allocation decisions in health care. At 
that time the focus was on clinical and cost-effective-
ness. During the subsequent two decades, health tech-
nology assessment bodies emerged. There was growing 
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recognition that other criteria are important, relating 
to equity, acceptability, burden and sustainability. More 
recently during the 2010s there has been growing inter-
est in decision analytic methods for considering multiple 
criteria, driven primarily by NICE in the UK and shifts to 
Value-Based Pricing. MCDA is a methodology designed 
to help decision-makers when making complex choices—
first developed in the 1960s and 1970s [44]. Health 
care decisions are complex and often involve trade-offs 
between conflicting and multiple objectives. Decision 
making involving either committees or individuals can 
involve difficulty in systematically evaluating all the rel-
evant information. The MCDA confronts trade-offs 
between alternatives under consideration and each deci-
sion maker prioritizes the most important.
Where a group is involved, the priorities of decision 
makers can conflict, rendering the decision-making pro-
cess very complex. Reliance on informal processes dur-
ing decision making can result in suboptimal decisions. 
A formal process such as MCDA is therefore required 
to evaluate alternatives and priorities to avoid inconsist-
ency, variability, or a lack of predictability on the impor-
tance of specific factors or criterions in the decision. 
MCDA provides clarity on which criteria are relevant, 
their relative importance and how the information can be 
used in a framework for assessing available alternatives. 
It is an extension of decision theory that covers any deci-
sion with multiple objectives (See Thokala et al. [45] for a 
review).
Whilst MCDA is used extensively in other sectors, 
recently health care applications have increased. Dur-
ing 2014, the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) established an 
MCDA Emerging Good Practices Task Force to establish 
a common MCDA approach in health care and develop 
associated good practice guidelines. MCDA is applied 
in various types of decision making in health care, 
including benefit risk analysis, health technology assess-
ment, resource allocation, portfolio decision analysis, 
shared patient clinician decision making and prioritizing 
patients’ access to services. It allows for the inclusion of 
preferences and social values [45].
MCDA approaches
MCDA approaches can be classified into value measure-
ment models, outranking models, and reference-level 
models [46].
  • Value measurement models develop and compare 
numerical scores to determine the extent to which 
one decision alternative is preferred over another. 
They often involve additive models—“weighted-sum” 
models, or “additive multi-attribute value models”. 
These multiply a numerical score for each alterna-
tive on a specific criterion by the relative weight for 
the criterion and then sum those weighted scores to 
determine a “total score” for each alternative.
  • Reference-level modelling searches for the alterna-
tive that is closest to attaining pre-defined minimum 
levels of performance on each criterion, using lin-
ear programming techniques and aspiration or goal 
methods.
  • Outranking methods make pair-wise comparisons of 
alternatives on each criterion which are combined to 
measure support for each alternative being judged 
the top-ranked alternative. Outranking algorithms 
include the Elimination and Choice Expressing Real-
ity (ELECTRE) methods, Preference Ranking Organ-
ization Method for Enrichment of Evaluations (PRO-
METHEE), and geometrical analysis for interactive 
aid (GAIA) (See Thokala et al. for a review) [45].
Value measurement approaches are the most widely 
used approach in health care. However, determining 
which MCDA model is most appropriate depends on the 
analysis and decision maker preferences [46].
Decision-makers in the health sector face a global 
challenge: how do we develop robust, evidence-based, 
scientific methods for priority setting? This challenge is 
often most evident in decisions concerning the coverage/
reimbursement of new drugs and technologies. Peacock, 
Mitton and Cromwell et  al. [44] indicated that a range 
of different criteria may be relevant for such decisions, 
including the effectiveness, cost-effectiveness and budget 
impact of the new drug; the incidence/prevalence and 
severity of the disease; the population group affected; the 
availability of alternative drugs/technologies; and, the 
quality of the available evidence [44].
When comparing new versus existing drugs/technolo-
gies these criteria will often need to be traded-off against 
one another. For example, a new drug may be more effec-
tive, but it may be costlier and targeted towards a smaller 
sub-population. MCDA can assist decision-makers make 
trade-offs when resources are constrained. When such 
trade-offs exist, MCDA offers a structured approach to 
evaluating and identifying a preferred option by scor-
ing and weighting the various attributes and deriving an 
aggregate ‘value’. This is in contrast with more traditional 
committee based approaches, where trade-offs either not 
discussed or are explored in a more qualitative manner.
Some key methodological issues and challenges iden-
tified by Peacock et  al. [44]. There are two main stages 
associated with MDCA, i.e. problem structuring and 
model building. Problem structuring involves generating 
a set of alternatives and a set of criteria against which the 
alternatives are evaluated and compared. Model building 
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involves constructing some form of model which repre-
sents decision-makers’ objectives and their value judge-
ments. A key consideration is the methods used to 
describe decision-makers preferences and ‘importance’ 
weights for decision-making criteria and the type of 
aggregation model used to combine criteria scores.
A simple model is:
where i = 1,…, n criteria; wi = criteria weights; j repre-
sents alternatives; sij = scores for alternatives for different 
criteria; WBS = Weighted Benefit Score.
Priority setting can be conceptualized as a continu-
ous quality-improvement reiterative process involving 
the following sequential steps: define the aim and scope; 
form an advisory panel of stakeholders; establish a pro-
gram budget, develop the decision criteria; identify and 
rank options; make decisions and specify the rationale; 
undertake a decision review process and finally, evalu-
ate and improve. The economic evidence and MCDA 
are applied at the decision criteria development stage 
through to decision making and rationale specification 
stage. A review of the literature identified 52 different cri-
teria listed in 14 studies, with the most commonly occur-
ring criteria, in descending order, including accessibility, 
reducing inequalities, effectiveness, alignment with stra-
tegic plan and policies, value for money, affordability and 
integration with other programs. Peacock et al. [44] com-
pared criteria used in Australia and Canada for cancer 
control and also for HTA agencies in Australia and the 
UK. These criteria are in Table 2.
A review of the literature concerning criteria weights in 
MCDA methods found that four studies did not report 
weights and seven studies used allocation of points 
(direct rating). Two studies used a combination of ratio 
estimation and direct rating. One study used indifference 
methods (DCEs). Previous studies have also used swing 
(1)WBSj =
n∑
i=1
wisij
weights (hybrid of indifference method). No studies have 
used gambles—all choices riskless [44].
With regard to MCDA methods for aggregation rules, 
Peacock et al. [44] found that where the aggregation rule 
was presented almost all (i.e. nine) applications used an 
additive functional form. Three did not state the func-
tional form used. One used an exponential function and 
another used a variant of the multiplicative function. 
Peacock et  al. found that the choice of functional form 
was rarely justified [44].
MCDA is useful from several perspectives. The primary 
aim of MCDA is to develop models of decision-maker 
objectives and their value trade-offs so that alternatives 
under consideration can be compared with each other 
in a consistent and transparent manner. The process is 
often more important than the numbers. It involves value 
focussed thinking and values clarification. MCDA prac-
tice suggests preferences are constructed as part of the 
decision-making process, not endowed. It is consistent 
with deliberative-analytic methods.
There are several issues that have arisen involving inter-
national consistencies and controversies in the decision 
criteria used in priority setting, the methods used to elicit 
criteria weights, and the complexity and transparency of 
the decision-making process. These fall into four broad 
methodological challenges. Firstly, how do we decide 
which stakeholder’s criteria will count—society, govern-
ments, private sector, patients, families, health provid-
ers, or other decision-makers? Second, which methods 
should be used to elicit and describe decision-makers 
preferences, including the relationship between objec-
tives and criteria. Further, the methods used to elicit 
importance weights for decision-making criteria can be 
controversial along with the type of aggregation model 
used to combine criteria scores.
Is there any common ground? Economics has often 
focussed on prescriptive behavioural rules, based on 
utility maximisation and game theory. On the other 
hand, psychology has sought to explain actual individual 
Table 2 Criteria developed by Cancer Control and HTA Agencies
Cancer control initiatives National HTA agencies
National cancer control initiative (Australia)
 Health gain-disability adjusted life years (DALYs)
 (Vertical) equity-reducing inequalities in mortality rates in vulnerable populations
 Size of health burden-disease burden in DALYs and cost to health system
 Acceptability and feasibility
NICE (England and Wales)
 Clinical effectiveness
 Cost-effectiveness
 Feasibility and impact
 Equity and equality
 Acceptability and appropriateness
British Columbia cancer control decision-makers (Canada)
 Health gain-quality adjusted life years (QALYs)
 Resource impact-budget constraints
 Resource impact- resource constraints
 Availability/advisability of alternatives
Pharmaceutical benefits advisory committee (Australia)
 Gap in current coverage
 Cost-effectiveness
 Effectiveness and safety
 Community need
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behaviour, and why it can deviate from prescriptive 
rules. Interestingly, decision analysis, including MCDA, 
endeavours to combine elements of both approaches 
through both ‘prescription’ with ‘practicality’. These 
approaches all share a common heritage from von Neu-
mann and Morgenstern [44].
ISPOR’s 2016s Task Force report provides good-
practice guidance on the implementation of MCDA 
for health care decisions. It incorporates a checklist to 
support the design, implementation and review of an 
MCDA; guidance to support checklist implementation; 
the sequencing of implemented steps and describes the 
incorporation of budget constraints into an MCDA. It 
also covers the skills and resources, including software, 
required to implement MCDA; and canvasses future 
research directions. ISPOR’s MCDA Good Practice 
Guidelines checklist is shown in Table  3 below. ISPOR 
also provides general guidance on the validation process 
in each step and on how to implement the other recom-
mendations in the checklist [47].
Several areas for further research have been identified 
by Marsh et  al. [47] to address the challenges associ-
ated with the technique, including the level of precision 
required of an MCDA; the cognitive challenges facing 
different types of stakeholders and the support that can 
overcome these challenges; decision makers’ preferences 
for the theoretical foundations of MCDA methods; which 
value functions best describe stakeholders preferences; 
and the best methods for incorporating uncertainty and 
budget constraints into an MCDA. Further, constructing 
a cost-benefit ratio using MCDA outputs faces several 
challenges including the different scales that are used to 
measure benefits and costs [47].
Inclusion of economic evidence in systematic reviews: 
recommendations after reviews on health policy impact 
and best practices
Systematic reviews are important in improving under-
standing of comparative effectiveness and relative value 
of medical interventions in health policy decisions and 
health guidelines [48]. A study by the Hopkins AHRQ 
project team addressed the appropriateness of incorpo-
rating economic data into systematic reviews of medical 
interventions in America. First, it examined if and how 
economic evidence impacts on health policy, including 
clinical guidelines, in the USA. It examined strengths and 
weaknesses of existing checklists used to assess best prac-
tices in economic evaluations. Finally, it reviewed studies 
addressing the use of economic outcomes in policy and 
decision making. The work is reported in publications by 
Niessen et al. [49], Walker et al. [50] and Frick et al. [51].
The review on economic evidence impacts on policy 
including clinical guidelines, used original studies applying 
quantitative or qualitative methods providing empirical 
data, in any country. The team excluded opinion or expe-
rienced-based articles without newly generated data. They 
defined ‘best-practice’ checklists as any original listing of 
recommendations that the authors used in economic eval-
uation. MEDLINE, EconLit, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), Embase®, and ISI 
Web of ScienceSM searched 1991 to January 2012. The lit-
erature was searched for articles on economic evaluations, 
Table 3 ISPOR MCDA good practice guidelines checklist (Source: Marsh et al. [47])
Defining the decision problem Develop a clear description of the decision problem
Validate and report the decision problem
Selecting and structuring criteria Report and justify the methods used to identify criteria
Report and justify the criteria definitions
Validate and report the criteria and the value tree
Measure performance Report and justify the sources used to measure performance
Validate and report the performance matrix
Scoring alternatives Report and justify the methods used for scoring
Validate and report scores
Weighting criteria Report and justify the methods used for weighting
Validate and report weights
Calculating aggregate scores Report and justify the aggregation function used
Validate and report results of the aggregation
Dealing with uncertainty Report sources of uncertainty
Report and justify the uncertainty analysis
Reporting and examining of findings Report the MCDA method and findings
Examine the MCDA findings
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outcomes, and guidelines for the decision maker. Paired 
reviewers independently determined whether articles met 
eligibility criteria and then extracted data.
Reviewers assessed the quality of each reporting study 
on policy impact using the standard grading recommenda-
tions (GRADE). Of 19,127 titles initially screened, 43 studies 
on policy impact were included, with all but five published 
since 2000. The most frequently studied countries were 
the United Kingdom (15), and Australia, Canada, and the 
United States (5 each). Most studies (27 studies) considered 
national-level policy and examined the key health actors 
involved. Important topics were reimbursement and health 
package decisions, and priority setting in programming. 
Thirty studies found evidence that use of economic evi-
dence had a substantial impact on health care policy mak-
ing, 27 of which emphasized at least one other criterion, 
such as equity considerations, usually ill-defined (14 stud-
ies), clinical effectiveness, budget impact, ethical reasons, 
and advocacy arguments. The thirty studies confirmed the 
acceptance of economic evidence as having an impact on 
either general policy or specific decisions, such as reim-
bursement decisions. Of 37 observational studies on policy 
impact, 11 (30%) received a favourable rating on more than 
three of the 8 items on the GRADE quality checklist. Five 
studies were graded of intermediate quality evidence [49].
The study concerning best practices for conducting 
economic evaluations in health care was a systematic 
review of quality assessment tools [50]. The objective 
was to describe strengths and weaknesses of checklists 
for conducting and reporting on economic evaluations in 
health care. The authors defined checklists as the original 
listings of specific items recommended in the conduct or 
reporting of an economic evaluation.
The study involved a review of the criteria for judging 
that an economic evaluation is of sufficiently high quality 
to be useful. It also considered the importance of differ-
ent aspects of the evaluation; and the extent to which high 
quality on one aspect of an evaluation can compensate 
for lower quality items. The methods involved a system-
atic search until January 2012 for articles and guidelines 
for decision makers. In MEDLINE, EconLit, CINAHL, 
Embase, and ISI Web of Science. They found that ten peer-
reviewed journal articles reported an original checklist. The 
first in 1992 and last in 2011 (EVEREST and CHEERS in 
2013). The number of items ranged from 11 to 57. Perspec-
tive was a criterion in all 10. The ten checklists reviewed 
included those by Adams [52], Gerard [53], Sacristan [54], 
Clemens [55]. The U.S. Panel, the British Medical Journal 
(BMJ) Checklist, The Paediatrics’ Quality Appraisal Ques-
tionnaire (PQAQ). The Quality of Health Economic Studies 
(QHES) list. The Consensus on Health Economic Criteria 
(CHEC) list and a checklist to frame health technology 
assessments for resource allocation decisions [52–62].
Eleven criteria were in 7–9 lists: including target popu-
lation, alternatives, study question, design, measurement, 
valuation, outcome identification, outcome measurement, 
time adjustment, sensitivity and uncertainties, presentation 
of results, generalizability, and incremental analysis. Four 
had evidence of excellent test–retest reliability: none had 
evidence of excellent inter-rater reliability in two or more 
studies. Three had evidence of excellent criterion validity, 
comparing checklists or expert ratings. They concluded 
that several well-developed checklists exist for investiga-
tors, reviewers, and journal editors to use in efforts to 
ensure more informative and transparent evidence [50].
They also analysed the usefulness of economic evalu-
ation data in systematic reviews of evidence [51]. This 
addressed the question: How useful is incorporating eco-
nomic evaluation data into systematic reviews of medical 
interventions? The method used was a consensus process 
with outside experts to develop a conceptual framework.
They found that all stakeholders, including insurers 
are interested in economic data and the perspectives of 
patients, providers, and manufacturers. Patients and pro-
viders determine the demand for care and manufactur-
ers determine the supply. Decisions are to be based on 
incremental cost, magnitude of the incremental effect, 
and the probability that economic evidence will change 
a decision. There is a high priority for evidence if there 
is a small effect at a high level of expenditure with a high 
probability of influencing a decision.
Economic data are of interest at many policy levels 
including approval and monitoring of services, formu-
lary inclusion, insurance coverage, reimbursement rate, 
preferred practice guideline, technology adoption or 
non-adoption, or clinical management. They may include 
information on cost-effectiveness, productivity changes 
related to disease, price data, responses to price changes. 
The following areas were of greatest interest: demand 
for care: time, distance, innovation price, price sensitiv-
ity, substitutes and complements, WTP, absenteeism and 
presentism. Supply of care was of interest including econ-
omy of scale, efficiency changes and return on invest-
ment. The equity and efficiency measures of particular 
interest were cost of illness studies; disease burden, Qual-
ity of life, budget impact, CEA ratio, net benefits and 
disparities. Existing economic data may be sufficient. 
Occasionally, it may be necessary to perform new evalua-
tions in case of inadequate data [51].
Conclusion
There is some evidence that Drummond’s 10-point 
checklist [11], when used in conjunction with Antioch 
et al.’s [10] questionnaire that scores Drummond’s check-
list, has resulted in cost-effective health care. These were 
used to grade economic evaluations, while integrating 
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economic evidence into CPGs by the Australian Local 
Hospital Networks that use both NHMRC and interna-
tional methodologies. That checklist and questionnaire 
can be used, in conjunction with the CHEERS 24 item 
checklist by health services, governments, NHMRC, 
other CPG organisations, and the ACSQHC for grad-
ing the economic evidence. Whilst the ten checklists 
reviewed by AHRQ are very useful, their limitations of 
inter-rater reliability can be addressed by including more 
than one assessor to reach a consensus on assessments. 
Especially when impacting on treatment decisions. Fur-
ther research could assess the impact of such checklists 
on the cost effectiveness of health services where they 
have been used to assess evidence for CPGs and treat-
ment decisions. Antioch et al. [10] questionnaire involves 
consensus by two assessors, given the impacts on treat-
ment decisions. The issues discussed concerning CEA 
thresholds, decision rules, opportunity costs, WTP and 
end of life therapies are also instructive world-wide. Pri-
ority setting is important and where trade-off decisions 
between criteria are required and MCDA is useful for 
Evidence Based Medicine and Evidence Based Planning. 
The Hopkins review identifies key priority areas for stud-
ies including the demand for care issues which can inves-
tigate time, distance, innovation price, price sensitivity, 
substitutes and complements, WTP, absenteeism and 
presentism. Supply of care issues can explore economies 
of scale, efficiency changes, and return-on-investments, 
equity and efficiency measures can include cost of illness 
studies, disease burden, quality of life, budget impact, 
CEA ratios, net benefits and disparities.
COAG, AHMAC, IHPA, ACSQHC and the Austral-
ian Department of Health could expedite the Australia-
wide dissemination of NHMRC’s methods on using the 
costs and benefits in CPGs and the subsequent revised 
methods. This may assist the health industry prepare for 
implementation of COAG’s 2016 Heads of Agreements 
on Public Hospital Funding which reduces ABF for speci-
fied adverse events, ineffective or harmful treatments 
and readmissions. IHPA, ACSQHC and COAG can risk 
adjust ABF and quality outcome measurement, through 
analysis of complexity markers for state-wide referral ser-
vices such as transplantation, major trauma and cystic 
fibrosis to enable equity.
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